InflaRx NV (IFRX) News

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology...

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

InflaRx Appoints Jan Medina as Head of Investor Relations

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory...